The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 05, 2023

Filed:

Mar. 13, 2018
Applicant:

Poseida Therapeutics, Inc., San Diego, CA (US);

Inventors:

Eric M. Ostertag, San Diego, CA (US);

Devon Shedlock, San Diego, CA (US);

Julian David Down, San Diego, CA (US);

Assignee:

Poseida Therapeutics, Inc., San Diego, CA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 9/00 (2006.01); A61K 31/664 (2006.01); A61K 31/7076 (2006.01); A61K 35/28 (2015.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); A61K 38/48 (2006.01); A61K 38/52 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C12N 5/0783 (2010.01); C12N 9/12 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 9/0019 (2013.01); A61K 9/0085 (2013.01); A61K 31/664 (2013.01); A61K 31/7076 (2013.01); A61K 35/28 (2013.01); A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 38/193 (2013.01); A61K 38/4873 (2013.01); A61K 38/52 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C12N 5/0636 (2013.01); C12N 9/1241 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12Y 207/07 (2013.01); C12Y 304/22062 (2013.01); C12Y 502/01008 (2013.01); C12N 2310/20 (2017.05); C12N 2510/00 (2013.01); C12N 2800/80 (2013.01);
Abstract

Disclosed are methods of eliminating at least on target cell in a subject, comprising administering to the subject an effective amount of a composition comprising a plurality of immune cells, wherein each immune cell of the plurality expresses one or more chimeric ligand receptor(s) (CLR(s)) that each specifically bind to a target ligand on the at least one target cell, wherein specifically binding of the one or more CLR(s) to the target activates the immune cell, and wherein the activated immune cell induces death of the target cell. Exemplary target cells include, but are not limited to, hematopoietic stem cells (HSCs).


Find Patent Forward Citations

Loading…